Literature DB >> 21563774

A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease.

Hao Li1, Lan Wang, Xianzhong Yan, Qijun Liu, Chaohui Yu, Handong Wei, Youming Li, Xuemin Zhang, Fuchu He, Ying Jiang.   

Abstract

This study was undertaken to discover novel biomarkers for the noninvasive early diagnosis of nonalcoholic fatty liver disease (NAFLD). A methionine and choline deficient (MCD) diet was used to represent different stages of NAFLD in male C57BL/6 mice. (1)H NMR spectroscopy and principal components analysis (PCA) were used to investigate the time-related biochemical changes in mice sera induced by the MCD diet. Many serum metabolites' concentrations changed between control and MCD-fed mice. Hierarchical cluster analysis (HCA) and artificial neural networks (ANNs) were used to select the least number of metabolites to be used for the noninvasive diagnosis of various stages of NAFLD; four potential biomarkers, serum glucose, lactate, glutamate/glutamine, and taurine were selected. To verify the diagnostic accuracy of these selected metabolites, their serum concentrations were measured in healthy controls (n = 28), NAFLD patients with steatosis (n = 15), steatosis patients with necro-inflammatory disease (n = 11), and NASH patients (n = 6). On the basis of results from MCD-fed mice model, clinical tests, and previous reports, we propose using the levels of the four metabolites for diagnosing NAFLD at various stages. Furthermore, the probability of developing NAFLD at a particular stage was assessed by multinomial logistic regression (MLR) based on the clinical results of the four serum metabolites.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21563774     DOI: 10.1021/pr200047c

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  28 in total

Review 1.  Clinical metabolomics paves the way towards future healthcare strategies.

Authors:  Sebastiano Collino; François-Pierre J Martin; Serge Rezzi
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 2.  Analysis of bacterial biofilms using NMR-based metabolomics.

Authors:  Bo Zhang; Robert Powers
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

Review 3.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

Review 4.  Metabonomic window into hepatitis B virus-related hepatic diseases.

Authors:  Qiang Hou; Zhi-Jun Duan
Journal:  World J Hepatol       Date:  2016-01-08

5.  Advances in Nutritional Metabolomics.

Authors:  Elizabeth P Ryan; Adam L Heuberger; Corey D Broeckling; Erica C Borresen; Cadie Tillotson; Jessica E Prenni
Journal:  Curr Metabolomics       Date:  2013

Review 6.  Biomarkers in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Lawrence B Cohen; Radu M Nanau
Journal:  Can J Gastroenterol Hepatol       Date:  2014-12

Review 7.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

8.  Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly.

Authors:  Jorge Simon; Maitane Nuñez-García; Pablo Fernández-Tussy; Lucía Barbier-Torres; David Fernández-Ramos; Beatriz Gómez-Santos; Xabier Buqué; Fernando Lopitz-Otsoa; Naroa Goikoetxea-Usandizaga; Marina Serrano-Macia; Rubén Rodriguez-Agudo; Maider Bizkarguenaga; Imanol Zubiete-Franco; Virginia Gutiérrez-de Juan; Diana Cabrera; Cristina Alonso; Paula Iruzubieta; Manuel Romero-Gomez; Sebastiaan van Liempd; Azucena Castro; Ruben Nogueiras; Marta Varela-Rey; Juan Manuel Falcón-Pérez; Erica Villa; Javier Crespo; Shelly C Lu; Jose M Mato; Patricia Aspichueta; Teresa C Delgado; María Luz Martínez-Chantar
Journal:  Cell Metab       Date:  2020-02-21       Impact factor: 27.287

9.  Glutamate-oxaloacetate transaminase activity promotes palmitate lipotoxicity in rat hepatocytes by enhancing anaplerosis and citric acid cycle flux.

Authors:  Robert A Egnatchik; Alexandra K Leamy; Sarah A Sacco; Yi Ern Cheah; Masakazu Shiota; Jamey D Young
Journal:  J Biol Chem       Date:  2018-12-18       Impact factor: 5.157

Review 10.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.